Non-Hodgkin lymphoma Posts on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

Evaluating high-dose cyclophosphamide for patients with hard-to-treat B-cell non-Hodgkin’s lymphoma

Posted by on Jan 12, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of high-dose cyclophosphamide (Cytoxan) for the treatment of relapsed or unresponsive non-Hodgkin’s lymphoma (NHL). This study concluded that high-dose cyclophosphamide was safe and effective for these patients. Some background Chemotherapy regimens remain a standard treatment...

Read More

Trends in outcomes of allogeneic transplantation for elderly patients with non-Hodgkin lymphoma

Posted by on Dec 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of allogeneic stem cell transplants (allo-SCT) in elderly patients with non-Hodgkin’s lymphoma (NHL). This study found that allo-SCT has improved survival outcomes for these patients. Some background Allogeneic stem cell transplantation (allo-SCT) can be highly effective for patients with...

Read More

Searching for patients with relapsed or unresponsive small lymphocytic lymphoma to test an immune cell-stimulating treatment

Posted by on Dec 19, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study is looking for patients with relapsed or unresponsive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to test IOV-2001, a treatment that boosts cancer-killing immune cells.  The main outcome that will be measured is how well patients respond to treatment. This study is recruiting in Columbus, OH, the...

Read More

Evaluating biosimilar rituximab for patients with non-Hodgkin’s lymphoma

Posted by on Dec 7, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the safety and effectiveness of BCD-020 (biosimilar rituximab) to rituximab (Rituxan) in patients with non-Hodgkin’s lymphoma (NHL). This study found that BCD-020 was just as effective as standard rituximab, with manageable side effects. Some background Rituximab is commonly used in the treatment of NHL....

Read More

My Oncologist Doesn’t Believe Food Is Necessary

My Oncologist Doesn’t Believe Food Is Necessary

Posted by on Dec 3, 2019 in Blog, Breast cancer, Colorectal cancer, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 3 comments

By Steve Gillman What my cancer taught me about medical “evidence” and how much is enough I exaggerate. My oncologist probably does believe humans need food, but I suspect the belief makes him uncomfortable, since no double-blind studies have been done to prove it. Like many doctors, his general approach to treatment is that if something hasn’t been...

Read More

Evaluating immune-related side effects associated with pembrolizumab.

Posted by on Nov 29, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study wanted to find out what put patients at risk of having immune-related side effects when they were treated with pembrolizumab (Keytruda). The study found that patients with a higher body mass index (BMI; a measurement of weight in relation to height) and more cycles of treatment were more likely to determine immune-related side...

Read More

Comparing chemotherapy dosing approaches for patients with non-Hodgkin lymphoma before a stem cell transplant

Posted by on Nov 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated two different dosing approaches for busulfan (Busilvex) chemotherapy for patients with non-Hodgkin lymphoma (NHL) before an autologous stem cell transplant (SCT). The authors found that personalizing treatment dose for these patients was more effective than conventional weight-based dosing. Some background...

Read More

Evaluating pembrolizumab for patients with primary mediastinal large B-cell lymphoma that has come back or stopped responding to treatment

Posted by on Nov 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) for patients with primary mediastinal large B-cell lymphoma (PMBCL) that has come back or stopped responding to treatment. This study concluded that pembrolizumab was safe and effective for these patients. Some background PMBCL is one rare and aggressive type...

Read More

How effective and safe is acalabrutinib compared to other treatments for patients with mantle cell lymphoma?

Posted by on Nov 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness and safety of acalabrutinib (Calquence) to other targeted therapies for patients with mantle cell lymphoma (MCL). The authors found that acalabrutinib was just as safe and more effective for these patients. Some background MCL is a type of non-Hodgkin's lymphoma treated in...

Read More

What factors can predict the success of stem cell transplantation for patients with non-Hodgkin lymphoma?

Posted by on Nov 3, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the risk factors associated with delayed engraftment (DE) in patients who had stem cell transplantation (SCT). The authors found that patients receiving blood transfusions, those with low platelet levels, and those given low numbers of stem cells during SCT were more likely to experience DE. Some background...

Read More